Health X Platform: Mar 2026: A Pharmacy Platform That Looks Like a Treasury

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Health X Platform trades at ₹281 (prices referenced are not live), a 465x current earnings multiple on reported FY26 net profit of ₹1.18 Cr—where the majority, ₹57.1 Cr, arrived as one-time treasury income.

Strip that out, the operating PAT is negative. Flip the lens: the company runs ₹1,319 Cr in annual revenue through a pharmacy supply network (B2B retailer Shakti and B2C SastaSundar), while holding ₹518.68 Cr in cash and investments—about 55% of market cap.

The market pays 0.68x sales, a fraction of listed diagnostics peers (2–14x). The tension: a platform with scale and zero debt, buried under treasury income and a restructuring scheme that will separate healthcare from finance.

What’s actually cooking underneath?

2. Introduction

Health X Platform (formerly Sastasundar Ventures) was incorporated in 1989 and spent its early decades as a holding vehicle. In 2022, it sat on ₹1,798 Cr revenue—a spike driven by consolidations. Since then, revenue has flattened (₹1,319 Cr in FY26, down from ₹1,432 Cr in FY24).

The core business is a digital pharmacy network: Retailer Shakti (B2B, supplying medicines to retail pharmacies), SastaSundar (B2C e-commerce and partnership with Flipkart Health+), and Genu Path Labs (diagnostics, nascent). The group also owns Microsec Resources, an NBFC focused on lending and wealth management—which will be demerged in a planned restructuring to arrive in FY27.

A name change to “Health X Platform” took effect in February 2026. The board approved a composite demerger and merger scheme in June 2026: the NBFC peels off into a separate listed entity, and Sastasundar Healthbuddy (the healthcare subsidiary) will merge into the parent, simplifying the structure.

The stock has given 1% absolute return over the past 12 months.

3. Business Model: WTF Do They Even Do?

Retailer Shakti (B2B Supply Chain)

A platform that supplies medicines, wellness, and FMCG to 65,000 retail pharmacies across India. The value pitch: next-day delivery, no credit (cash/bank transfers only), and pricing 1.5–2% better than traditional distributors. Management claims this forces retailers into less than 1% credit cost via NBFC/bank loans, offsetting the credit-free model.

The network is lean and capital-efficient: receivables sit at ₹7.66 Cr (2.1 debtor days), inventory at ₹144.65 Cr (44 inventory days). No cash burn on credit float. The moat is speed and transparency, not lock-in.

Growth has stalled: management attributed prior quarter slowness to automation bottlenecks at the Baruipur fulfillment center (West Bengal). Capex expansion underway: ₹10 Cr for 80,000 sq ft in WB, plus new centers in Noida (1 lakh sq ft, 1.5 year timeline) and Northeast.

SastaSundar B2C + HealthBuddy Local

The B2C arm sells medicines, diagnostics, and wellness via app and a network of 293 local “HealthBuddy” centers (target 400 by Mar 2027). Orders are 100% digital; HealthBuddies handle last-mile. Management claims the model is “contribution-positive” at the gross margin level, with investment only in salaries and ads (₹15 Cr + ₹11 Cr stated).

The reality is opaque: the concall framed it as “cash positive,” but the P&L shows consolidated losses. The unit economics story relies on management narrative alone; public financials don’t isolate the segment.

JITO (New Private Label)

Launched in Q3 FY26: a private-label generic-generic program sold through the retailer network. Stated unit economics are 30% gross margin and 25% contribution margin—much higher than the core distribution (7–8% gross). Management targets 2–3% of revenue mix next year, scaling to 10% in 3–4 years.

This is the only material margin expansion play in the pipeline.

4. Financials Overview

Figures are consolidated, in ₹ crore.

What Happened

FY26 revenue grew 13.9% YoY, reversing FY25 decline. EBITDA swung from -₹12 Cr to +₹104.5 Cr—a seemingly dramatic recovery, except the concall revealed the nuance: operating EBIT was close to breakeven (Q3: ₹1 Cr), propped by ₹57.14 Cr in other income (treasury gains, most likely from the Flipkart Health+ stake sale in Oct 2024 where the company realized gains).

Operating profit (from P&L sheet) was ₹111 Cr—respectable until you account for the fact that ₹57 Cr of “other income” is a one-timer. Strip it: operating PAT ≈ ₹1.18 – ₹57.14 ≈ -₹56 Cr.

The core business is not yet profitable.

FY25 was a bloodbath: ₹178.77 Cr loss in other income (a reversal or impairment, likely), PAT down to -₹91.2 Cr.

Management guidance (from Feb 2026 concall):

• Retailer Shakti to achieve EBITDA breakeven by Q4 FY26, EBITDA-positive in FY27.
• B2C to reach contribution-margin positive in FY27, PAT positive in FY28–29.

These are target statements, not forecasts. Execution risk is material.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market currently pays 465x earnings here, against a peer band of 47x (industry median) and 50–97x for diagnostics peers like Dr Lal Pathlabs and Vijaya Diagnostics.

The P/E is inflated by near-zero earnings. Strip to EV/EBITDA: at ₹889 Cr EV and ₹104.5 Cr EBITDA (heavily treasury-weighted), the multiple is 8.5x—closer to wholesale/distribution norms (5–12x). On an operational basis, if EBIT is ₹1 Cr, the EV/EBIT is 889x, a price for faith in turnaround.

P/Sales of 0.68x sits below peers (2–14x), a reflection